Authors: Sanjay Kalra & Nitin Kapoor
Abstract
Glucagon-like peptide 1 receptor agonists (GLP1RAs) have recently gained momentum after the introduction of semaglutide, the first oral molecule in their class. In a recent article in this journal by Evans et al., a succinct overview of the utility of semaglutide is highlighted in the context of virtual diabetes care. To take this discussion further, this commentary describes the value and positioning of oral semaglutide in common clinical situations. Its insights assist in pragmatic placement of this drug in clinical practice. Special emphasis is laid on the use of oral semaglutide in persons already on injectable GLP-1RA formulations, those experiencing sudden changes in life style pattern due to religious, social, or professional commitments, individuals seeking help for urgent glycemic control, and those who face sudden change in their concomitant medications or comorbidities.
Key Summary Points |
Glucagon-like peptide 1 receptor agonists (GLP1RAs) have recently gained momentum after the introduction of semaglutide, the first oral molecule in their class. |
This manuscript describes the value and positioning of oral semaglutide in common clinical situations. Specific tips on how to prescribe this drug in a large spectrum of people living with type 2 diabetes are mentioned. |
The utility of oral semaglutide in those using injectable GLP-1RA formulations, those having sudden changes in their life style pattern due to religious, social, or professional commitments, those seeking help for urgent glycemic control, or those experiencing a sudden change in their concomitant medications or comorbidities is explained. |